KALA BIO, Inc.
NASDAQ Global SelectTotal Valuation
KALA BIO, Inc. carries a market capitalization of 16.08M, placing it among publicly traded companies globally. Its enterprise value stands at -7.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 16.08M |
| Enterprise Value | -7.30M |
Share Statistics
KALA BIO, Inc. currently has 18.59M shares outstanding.
| Shares Outstanding | 18.59M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.14 |
| P/FCF Ratio | -0.06 |
| P/OCF Ratio | -0.06 |
Financial Position
KALA BIO, Inc. maintains a current ratio of 7.91, meaning it holds 7.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 7.91 |
| Quick Ratio | 5.68 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -14.78 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -64.90 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -1.40 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
KALA BIO, Inc.'s stock has declined approximately -99.74267% over the past 52 weeks. The 50-day moving average sits at 2.32, while the 200-day moving average is 22.36.
| Beta (5Y) | N/A |
| 52-Week Price Change | -99.74267% |
| 50-Day Moving Average | 2.32 |
| 200-Day Moving Average | 22.36 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -32.29M, while operating income came in at -32.54M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -32.54M |
| Pretax Income | -19.65M |
| Net Income | -19.65M |
| EBITDA | -32.29M |
| EBIT | -32.54M |
| Earnings Per Share (EPS) | -115.93 |
Balance Sheet
Total book value stands at -696.50M, with working capital of 10.76M providing operational flexibility.
| Cash & Cash Equivalents | 8.76M |
| Total Debt | N/A |
| Net Debt | -1.76M |
| Equity (Book Value) | -696.50M |
| Book Value Per Share | -4,108.49 |
| Working Capital | 10.76M |
Cash Flow
KALA BIO, Inc. produced -26.06M in operating cash flow over the past twelve months. After subtracting -15,000.00 in capital expenditures, free cash flow totaled -26.08M - equivalent to -153.82 per share.
| Operating Cash Flow | -26.06M |
| Capital Expenditures | -15,000.00 |
| Free Cash Flow | -26.08M |
| FCF Per Share | -153.82 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 503.34 |
| FCF Yield | -1,776.24 |
Stock Splits
KALA BIO, Inc.'s most recent stock split took place on May 11, 2026 with a 50:1 split ratio.
| Last Split Date | 5/11/2026 |
| Split Ratio | 50:1 |
Scores
KALA BIO, Inc. posts an Altman Z-Score of -86.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -86.27 |